Treating hypogonadism in younger males

Expert Opinion on Pharmacotherapy

Volumn 11, Issue 9, 2010, Pages 1529-1540

  Yin, Anthony ^a   Swerdloff, Ronald ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Androgen deficiency; Delayed puberty; Dihydrotestosterone; Disorder of sexual development; Human chorionic gonadotropin; Hypogonadism; Induction of puberty; Kallmann's syndrome; Klinefelter syndrome; Testosterone

Indexed keywords

ANDROSTANOLONE; AXIRON; CHORIONIC GONADOTROPIN; FOLLITROPIN; LUTEINIZING HORMONE; METHYLTESTOSTERONE; PROSTATE SPECIFIC ANTIGEN; RECOMBINANT FOLLITROPIN; SELECTIVE ANDROGEN RECEPTOR MODULATOR; TESTOLACTONE; TESTOSTERONE; TESTOSTERONE CIPIONATE; TESTOSTERONE ENANTATE; TESTOSTERONE UNDECANOATE; TOSTRAN; UNCLASSIFIED DRUG;

ANDROGEN DEFICIENCY; ANDROGEN THERAPY; BLISTER; BLOOD SAMPLING; BONE AGE; CANCER RISK; CANCER SCREENING; CARDIOVASCULAR RISK; CLINICAL DECISION MAKING; COUGHING; DRUG DOSE INCREASE; DRUG IMPLANT; DRUG INFORMATION; DRUG LABELING; DRUG MONITORING; DRUG WITHDRAWAL; ERYTHEMA; ERYTHROCYTOSIS; FAMILY HISTORY; FOLLITROPIN BLOOD LEVEL; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; HUMAN; HYPERGONADOTROPIC HYPOGONADISM; HYPOGONADISM; HYPOGONADOTROPIC HYPOGONADISM; HYPOTHALAMUS HYPOPHYSIS GONAD SYSTEM; LONG TERM CARE; LUTEINIZING HORMONE BLOOD LEVEL; NON INSULIN DEPENDENT DIABETES MELLITUS; PHLEBOTOMY; PRACTICE GUIDELINE; PREPUBERTY; PROLACTIN BLOOD LEVEL; PROSTATE BIOPSY; PROSTATE CANCER; PUBERTY; REPEAT PROCEDURE; REVIEW; RISK FACTOR; SEXUAL DEVELOPMENT; SPERMATOGENESIS; TESTOSTERONE BLOOD LEVEL; TREATMENT CONTRAINDICATION;

ADOLESCENT; ADULT; CHILD, PRESCHOOL; HUMANS; HYPOGONADISM; MALE; MIDDLE AGED; TESTOSTERONE;

EID: 77952726774     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656561003742947     Document Type: Review

References (63)

1. Peng X, Zeng X, Peng S, et al. The association risk of male subfertility and testicular cancer: a systematic review. PLoS One 2009;4:e5591
2. Raman JD, Nobert CF, Goldstein M. Increased incidence of testicular cancer in men presenting with infertility and abnormal semen analysis. J Urol 2005;174:1819-1822
3. Kronenberg HM, Larsen PR, editor, Williams textbook of endocrinology. 11th edition. Saunders; 7 A.D
4. McCullagh DR. Dual endocrine activity of the testes. Science 1932;76:19-20
5. Zirkin BR, Awoniyi C, Griswold MD, et al. Is FSH required for adult spermatogenesis? J Androl 1994;15:273-276
6. Rogol AD. New facets of androgen replacement therapy during childhood and adolescence. Expert Opin Pharmacother 2005;6:1319-1336
7. Mauras N, Hayes V, Welch S, et al. Testosterone deficiency in young men: marked alterations in whole body protein kinetics, strength, and adiposity. J Clin Endocrinol Metab 1998;83:1886-1892
8. Bhasin S, Bagatell CJ, Bremner WJ, et al. Issues in testosterone replacement in older men. J Clin Endocrinol Metab 1998;83:3435-3448
9. Morley JE, Kaiser FE, Perry HM III, et al. Longitudinal changes in testosterone, luteinizing hormone, and follicle-stimulating hormone in healthy older men. Metabolism 1997;46:410-413
10. Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2006;91:1995-2010
11. Hughes IA, Houk C, Ahmed SF, Lee PA. Consensus statement on management of intersex disorders. J Pediatr Urol 2006;2:148-162 (Pubitemid 43840887)
12. Ambler GR. Androgen therapy for delayed male puberty. Curr Opin Endocrinol Diabetes Obes 2009;16:232-239
13. Bertelloni S, Dati E, Baroncelli GI. Disorders of sex development: hormonal management in adolescence. Gynecol Endocrinol 2008;24:339-346
14. Walvoord E. Sex steroid replacement for induction of puberty in multiple pituitary hormone deficiency. Pediatr Endocrinol Rev 2009;6(Suppl 2):298-305
15. Pozo J, Argente J. Ascertainment and treatment of delayed puberty. Horm Res 2003;60(Suppl 3):35-48
16. Mauras N, Haymond MW, Darmaun D, et al. Calcium and protein kinetics in prepubertal boys. Positive effects of testosterone. J Clin Invest 1994;93:1014-1019
17. Skakkebaek NE, Bancroft J, Davidson DW, Warner P. Androgen replacement with oral testosterone undecanoate in hypogonadal men: a double blind controlled study. Clin Endocrinol (Oxf) 1981;14:49-61
18. Nieschlag E, Buchter D, von ES, et al. Repeated intramuscular injections of testosterone undecanoate for substitution therapy in hypogonadal men. Clin Endocrinol (Oxf) 1999;51:757-763 (Pubitemid 30050826)
19. Jain P, Rademaker AW, McVary KT. Testosterone supplementation for erectile dysfunction: results of a meta-analysis. J Urol 2000;164:371-375
20. Steidle C, Schwartz S, Jacoby K, et al. AA2500 testosterone gel normalizes androgen levels in aging males with improvements in body composition and sexual function. J Clin Endocrinol Metab 2003;88:2673-2681
21. Wang C, Cunningham G, Dobs A, et al. Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. J Clin Endocrinol Metab 2004;89:2085-2098
22. Pope HG Jr, Cohane GH, Kanayama G, et al. Testosterone gel supplementation for men with refractory depression: a randomized, placebo-controlled trial. Am J Psychiatry 2003;160:105-111
23. McNicholas TA, Dean JD, Mulder H, et al. A novel testosterone gel formulation normalizes androgen levels in hypogonadal men, with improvements in body composition and sexual function. BJU Int 2003;91:69-74
24. Wang C, Swerdloff RS, Iranmanesh A, et al. Effects of transdermal testosterone gel on bone turnover markers and bone mineral density in hypogonadal men. Clin Endocrinol (Oxf) 2001;54:739-750
25. Snyder PJ. Effects of age on testicular function and consequences of testosterone treatment. J Clin Endocrinol Metab 2001;86:2369-2372
26. Coward RM, Simhan J, Carson CC III. Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy. BJU Int 2009;103:1179-1183
27. Schleich F, Legros JJ. Effects of androgen substitution on lipid profile in the adult and aging hypogonadal male. Eur J Endocrinol 2004;151:415-424
28. Pfeil E, Dobs AS. Current and future testosterone delivery systems for treatment of the hypogonadal male. Expert Opin Drug Deliv 2008;5:471-481
29. Meikle AW, Mazer NA, Moellmer JF, et al. Enhanced transdermal delivery of testosterone across nonscrotal skin produces physiological concentrations of testosterone and its metabolites in hypogonadal men. J Clin Endocrinol Metab 1992;74:623-628
30. ANDROGEL. Solvay Pharmaceuticals, 2009. Available from: http://www. solvaypharmaceuticals.com/Products/ group/product/0,30643-2-0,00.htm. [Last accessed 9 November 2009]
31. Bentley Granted European Patent for Its Testosterone Gel. Business Wire, 2007. Available from: http://www.allbusiness.com/legal/ intellectual-property- law/5249773-1.html. [Last accessed 9 November 2009]
32. Androgel (Testosterone Gel for Topical Use) Drug Information. RxList, 2009. Available from: http://www.rxlist.com/androgel-drug.htm. [Last accessed 22 November 2009]
33. Wang C, Berman N, Longstreth JA, et al. Pharmacokinetics of transdermal testosterone gel in hypogonadal men: application of gel at one site versus four sites: a General Clinical Research Center Study. J Clin Endocrinol Metab 2000;85:964-969
34. Han TS, Bouloux PM. What is the optimal therapy for young males with hypogonadotrophic hypogonadism? Clin Endocrinol (Oxf) 2009. [Epub ahead of print]
35. de Ronde W. Hyperandrogenism after transfer of topical testosterone gel: case report and review of published and unpublished studies. Hum Reprod 2009;24:425-428
36. Richman RA, Kirsch LR. Testosterone treatment in adolescent boys with constitutional delay in growth and development. N Engl J Med 1988;319:1563-1567
37. Wang C, Swerdloff R, Kipnes M, et al. New testosterone buccal system (Striant) delivers physiological testosterone levels: pharmacokinetics study in hypogonadal men. J Clin Endocrinol Metab 2004;89:3821-3829
38. STRIANT - Professional - STRIANT Patient Booklet. STRIANT Patient Booklet, 2010. Available from: http://www.striant.com/Professional/ patient-booklet/patient-booklet. asp#FAQs. [Last accessed 6 January 2010]
39. Kelleher S, Conway AJ, Handelsman DJ. A randomised controlled clinical trial of antibiotic impregnation of testosterone pellet implants to reduce extrusion rate. Eur J Endocrinol 2002;146:513-518
40. Kinniburgh D, Zhu H, Cheng L, et al. Oral desogestrel with testosterone pellets induces consistent suppression of spermatogenesis to azoospermia in both Caucasian and Chinese men. Hum Reprod 2002;17:1490-1501
41. Cavender RK, Fairall M. Subcutaneous testosterone pellet implant (Testopel) therapy for men with testosterone deficiency syndrome: a single-site retrospective safety analysis. J Sex Med 2009;6:3177-3192
42. Acrux Announces Axiron Phase III Results. Wireless News Newspaper, 2010. Available from: http://findarticles. com/p/news-articles/wireless-news/ mi-hb5558/is-20091003/acruxannounces- axiron-phase-iii/ai-n39986194. [Last accessed 30 December 2010]
43. News: Acrux' Testosterone Treatment Triumphs in Phase III Study. Genetic Engineering & Biotechnology News, 2010. Available from: http://www. genengnews.com/news/ bnitem.aspx?name=64091122. [Last accessed 26 November 2009]
44. Axiron Fact Sheet 2009. www acrux com au, 2010. Available from: http://www.acrux.com.au/IRM/ Company/ShowPage.aspx?CPID=1417. [Last accessed 14 January 2010]
45. Available from: http://xpil.medicines.org. uk/ViewPil.aspx?DocID=19703. medicines org uk, 2010. [Last accessed 14 January 2010]
46. Barrio R, de LD, Alonso M, et al. Induction of puberty with human chorionic gonadotropin and follicle-stimulating hormone in adolescent males with hypogonadotropic hypogonadism. Fertil Steril 1999;71:244-248
47. Warne DW, Decosterd G, Okada H, et al. A combined analysis of data to identify predictive factors for spermatogenesis in men with hypogonadotropic hypogonadism treated with recombinant human follicle-stimulating hormone and human chorionic gonadotropin. Fertil Steril 2009;92:594-604
48. Vicari E, Mongioi A, Calogero AE, et al. Therapy with human chorionic gonadotrophin alone induces spermatogenesis in men with isolated hypogonadotrophic hypogonadism--long-term follow-up. Int J Androl 1992;15:320-329
49. Gordon D, Lauder JC, Cohen HN, et al. An evaluation of human chorionic gonadotrophin (HCG) therapy in boys with delayed puberty. Q J Med 1990;74:247-256
50. de Ronde W. Therapeutic uses of aromatase inhibitors in men. Curr Opin Endocrinol Diabetes Obes 2007;14:235-240
51. Pavlovich CP, King P, Goldstein M, Schlegel PN. Evidence of a treatable endocrinopathy in infertile men. J Urol 2001;165:837-841
52. Odame I, Donaldson MD, Wallace AM, et al. Early diagnosis and management of 5 alpha-reductase deficiency. Arch Dis Child 1992;67:720-723
53. Charmandari E, Dattani MT, Perry LA, et al. Kinetics and effect of percutaneous administration of dihydrotestosterone in children. Horm Res 2001;56:177-181
54. Wang C, Iranmanesh A, Berman N, et al. Comparative pharmacokinetics of three doses of percutaneous dihydrotestosterone gel in healthy elderly men--a clinical research center study. J Clin Endocrinol Metab 1998;83:2749-2757
55. Rhoden EL, Morgentaler A. Influence of demographic factors and biochemical characteristics on the prostate-specific antigen (PSA) response to testosterone replacement therapy. Int J Impot Res 2006;18:201-205
56. Arrigo T, Cisternino M, Luca DF, et al. Final height outcome in both untreated and testosterone-treated boys with constitutional delay of growth and puberty. J Pediatr Endocrinol Metab 1996;9:511-517
57. Buyukgebiz A. Treatment of constitutional delayed puberty with a combination of testosterone esters. Horm Res 1995;44(Suppl 3):32-34
58. Caruso-Nicoletti M, De Sanctis V, Raiola G, et al. No difference in pubertal growth and final height between treated hypogonadal and non-hypogonadal thalassemic patients. Horm Res 2004;62:17-22
59. Professional - STRIANT Prescribing Information. STRIANT, 2010. Available from: http://www.striant.com/Professional/ prescribing-info/prescribing-info. asp. [Last accessed 14 January 2010]
60. Depo®-Testosterone, testosterone cypionate injection, USP. Pfizer, 2010. Available from: http://www.pfizer.com/files/products/ uspi-depo- testosterone.pdf. [Last accessed 14 January 2010]
61. Nebido: Summary of Product Characteristics (SPC). emc medicines org uk,2010. Available from: http://emc.medicines.org.uk/ medicine/15661/SPC/Nebido+ 1000mg+4ml,+solution+for+injection# PHARMACOKINETIC-PROPS. [Last accessed 14 January 2010]
62. Testopel: Prescription Drug Information, Side Effects. PDRHealth, 2010. Available from: http://www.pdrhealth.com/drugs/rx/ rx-mono.aspx?contentFileName= tes1595.html&contentName=Testopel& contentId=754. [Last accessed 14 January 2010]
63. Jockenhovel F, Vogel E, Kreutzer M, et al. Pharmacokinetics and pharmacodynamics of subcutaneous testosterone implants in hypogonadal men. Clin Endocrinol (Oxf) 1996;45:61-71